Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Manuel Vidal Sanz, European Association for Vision and Eye Research: Presidential Update 2022 Part 1

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 14th 2022

The European Association for Vision and Eye Research (EVER) is the leading ophthalmological research association in Europe, which covers all areas of ophthalmology and the visual sciences. One of the main activities of EVER is the organizing of a high quality research meeting every year at a location chosen for its access and congress facilities. EVER collaborates closely with other societies in organizing joint meetings during EVER.

touchOPHTHALMOLOGY caught up with the President of EVER, Manuel Vidal Sanz, to discuss the objectives of the Association in 2022 and its research priorities.

For more information, please visit: https://www.everassociation.org/

Questions:

  1. What are the objectives of EVER? (00:17)
  2. What are the major challenges faced by the ophthalmology community at the moment? (02:04)
  3. What are EVER’s research priorities for the coming year? (04:08)

Disclosures: Manuel Vidal Sanz has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup